China Resources once again increased its holdings in Dong'agum, stressing "state-owned holding"

Pharmaceutical Network February 3, the evening of The East Agar announced that China Resources Pharmaceutical Investment Co., Ltd(hereinafter referred to as "China Resources Pharmaceutical Investment") increased its holding of 32.7108 million shares from April 20, 2016 to January 25, 2017, accounting for 5% of the company's total share capitalThe cost of investing in this round of investment in China Resources Pharmaceuticals is 43.99 to 55 yuan per share, at a cumulative cost of 1.5 billion yuan, China Resources held a 23.14 percent stake in Dong'agum before the increaseIn other words, China Resources now controls 28.14 percent of Dong'agum, close to 30 percent of the offer to buy the red lineChina Resources this increase in the main body of China Resources Pharmaceutical Investment, rather than the long-term East Agum's largest shareholder, China Resources East Aa, if the layout or deep meaningIn the detailed changes in equity, China Resources Pharmaceutical Investment said it would not rule out continuing to increase its holdings in the next 12 monthsChina Resources Pharmaceutical Investment is the controlling shareholder of China Resources Donga, before this round of increase, did not directly hold the shares of Dong'a gumFor a long time, China Resources Donga is China Resources in The East A gum's only holding platformEquity report also made it clear that China Resources East A is China Resources Pharmaceutical Investment's Dong Agum holding platform, the scope of business for the development of Agu series of products, investment managementhowever, in April last year, the holding platform began to change, China Resources Pharmaceutical Investment began to buy directly in Dong'a gumAt noon on June 21, 2016, Dong'a-Glue announced that from April 20, 2016 to May 5, 2016, China Resources Pharmaceutical Investment increased its stake in the Company by 30,476.1 million shares through the secondary market, accounting for 4.66% of the total number of shares issued by the Companyat that time, China Resources Pharmaceutical Investment gave the purpose of maintaining the company's long-term strategic stability, better play the overall advantages and synergies of China Resources Group, enhance the company's profitability and comprehensive competitiveness, boost the confidence of the capital market, and realize the preservation and appreciation of state-owned assets and shareholder valuelook at today's announcement, adding a sentence to the list edding: "Based on the ability to consolidate the control and decision-making power of state-owned shareholders over its listed companies", other content is the same as last yearAccording to data from the third-quarter report of dongagu last year, the other shareholders of the company are far less owned by China Resources, with the third-largest shareholder, Seinco Holding 2.35 per centThe remaining other shareholders held less than 2%the list of shareholders in Dong'a gum a lot of risk, Pacific Life, Qianhai Life, Anbang's products appear in the top ten shareholders Therefore, there are industry analysts, China Resources's large increase in holdings is to resist the "barbarians", to prevent The Baowan controversy in the East Agum staged plays an important role in China Run's medicine On October 28 last year, China Resources Pharmaceuticals (03320 HK) is officially listed in Hong Kong China Resources Pharma through China Resources Pharmaceutical Holdings as a holding platform for pharmaceutical assets, China Resources Pharmaceutical Investment is China Resources Pharmaceutical Holdings in addition to China Resources 39 other pharmaceutical assets holding platform, the scope of business for enterprises
investment management and enterprise investment consulting China Resources' pharmaceutical layout in the A-share has three listed companies, the other two are China Resources 39 and China Resources Shuanghe, are in a controlling position